Cargando…

Conservative management of CIN2 p16 positive lesions in women with multiple HPV infection

BACKGROUND: According to the 2006 American Society for Colposcopy and Cervical Pathology guidelines, positive CIN2 p16 in women over the age of 25 should be managed with excisional treatment. However, excisional treatment is associated with physical, psychological and obstetric morbidity and can hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruno, Maria Teresa, Scalia, Guido, Cassaro, Nazario, Costanzo, Maria, Boemi, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597054/ https://www.ncbi.nlm.nih.gov/pubmed/33121447 http://dx.doi.org/10.1186/s12879-020-05530-5

Ejemplares similares

Multiple HPV 16 infection with two strains: a possible marker of neoplastic progression
por: Bruno, Maria Teresa, et al.
Publicado: (2020)

Progression of CIN1/LSIL HPV Persistent of the Cervix: Actual Progression or CIN3 Coexistence
por: Bruno, Maria Teresa, et al.
Publicado: (2021)

Possible role of negative human papillomavirus E6/E7 mRNA as a predictor of regression of cervical intraepithelial neoplasia 2 lesions in hr-HPV positive women
por: Bruno, Maria Teresa, et al.
Publicado: (2022)

HPV16 persistent infection and recurrent disease after LEEP
por: Bruno, Maria Teresa, et al.
Publicado: (2019)

Spontaneous regression of cervical intraepithelial neoplasia 3 in women with a biopsy—cone interval of greater than 11 weeks
por: Bruno, Maria Teresa, et al.
Publicado: (2022)

HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions
por: Mariani, Luciano, et al.
Publicado: (2016)

Oral HPV Infection in Women with HPV-Positive Cervix Is Closely Related to Oral Sex
por: Bruno, Maria Teresa, et al.
Publicado: (2023)

HPV Tests Comparison in the Detection and Follow-Up after Surgical Treatment of CIN2+ Lesions
por: Bottari, Fabio, et al.
Publicado: (2022)

Usefulness of E7 mRNA in HPV16-Positive Women to Predict the Risk of Progression to HSIL/CIN2+
por: Martí, Cristina, et al.
Publicado: (2021)

Therapeutic vaccination using HPV 16 E7 to eradicate CIN3
por: Tewari, Krishnansu S.
Publicado: (2019)

HPV16 variant analysis in primary and recurrent CIN2/3 lesions demonstrates presence of the same consensus variant
por: van der Weele, Pascal, et al.
Publicado: (2019)

Clinical and analytical performance of the BD Onclarity™ HPV assay for detection of CIN2+ lesions on SurePath samples
por: Ejegod, Ditte Møller, et al.
Publicado: (2016)

Evidence for HPV DNA in the placenta of women who resorted to elective abortion
por: Bruno, Maria Teresa, et al.
Publicado: (2021)

Consistent condom use increases spontaneous regression in high-risk non-HPV16 but not in HPV16 CIN2-3 lesions, a prospective population-based cohort study
por: Munk, Ane Cecilie, et al.
Publicado: (2012)

Combining HPV DNA load with p16/Ki-67 staining to detect cervical precancerous lesions and predict the progression of CIN1–2 lesions
por: Li, Yuejie, et al.
Publicado: (2019)

Papillomavirus Infection as Potential Cause of Miscarriage in the Early Gestational Age: A Prospective Study
por: Bruno, Maria Teresa, et al.
Publicado: (2023)

Improving the Quality of Healthcare Provision Regarding HPV Immunization for Women with CIN2+ Lesions: The Experience of the Veneto Region in Italy
por: De Polo, Anna, et al.
Publicado: (2023)

Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort
por: Bonde, Jesper, et al.
Publicado: (2019)

HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test
por: Polman, Nicole J, et al.
Publicado: (2017)

Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients
por: Kim, Tae Jin, et al.
Publicado: (2014)

Evaluating HPV‐negative CIN2+ in the ATHENA trial
por: Petry, Karl Ulrich, et al.
Publicado: (2016)

Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials
por: Ibrahim Khalil, Ahmadaye, et al.
Publicado: (2023)

The Accuracy of p16/Ki-67 and HPV Test in the Detection of CIN2/3 in Women Diagnosed with ASC-US or LSIL
por: Possati-Resende, Júlio C., et al.
Publicado: (2015)

Effect of Condom Use after CIN Treatment on Cervical HPV Biomarkers Positivity: Prolonged Follow Up Study
por: Valasoulis, George, et al.
Publicado: (2022)

Underdiagnosis of cervical intraepithelial neoplasia (CIN) 2 or Worse Lesion in Women with a Previous Colposcopy-Guided Biopsy Showing CIN 1
por: Souza, Carlos André Scheler de, et al.
Publicado: (2017)

Temporal changes in the vaginal microbiota in self-samples and its association with persistent HPV16 infection and CIN2+
por: Berggrund, Malin, et al.
Publicado: (2020)

Overexpression of E6/E7 mRNA HPV Is a Prognostic Biomarker for Residual Disease Progression in Women Undergoing LEEP for Cervical Intraepithelial Neoplasia 3
por: Bruno, Maria Teresa, et al.
Publicado: (2023)

Adjunctive use of p16 immunohistochemistry for optimizing management of CIN lesions in a high‐risk human papillomavirus‐positive population
por: Ebisch, Renée M. F., et al.
Publicado: (2022)

Impact of HPV mRNA types 16, 18, 45 detection on the risk of CIN3+ in young women with normal cervical cytology
por: Al-Shibli, Khalid, et al.
Publicado: (2022)

E2/E6 ratio and L1 immunoreactivity as biomarkers to determine HPV16-positive high-grade squamous intraepithelial lesions (CIN2 and 3) and cervical squamous cell carcinoma
por: Choi, Youn-Jin, et al.
Publicado: (2018)

Performance of p16/Ki67 Immunostaining for Triage of Elderly Women with Atypical Squamous Cells of Undetermined Significance
por: Bruno, Maria Teresa, et al.
Publicado: (2023)

An Adsorptive and Antioxidant Vaginal Gel Clears High-Risk HPV- and p16/Ki-67-Associated Abnormal Cytological Cervical Findings: A post-hoc Subgroup Analysis of a Prospective Randomized Controlled Trial on CIN2 and p16 Positive CIN1
por: Major, Attila Louis, et al.
Publicado: (2021)

Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years
por: Paaso, Anna, et al.
Publicado: (2015)

Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing
por: Kocken, M, et al.
Publicado: (2012)

HPV-16 Infection Is Associated with a High Content of CD39 and CD73 Ectonucleotidases in Cervical Samples from Patients with CIN-1
por: de Lourdes Mora-García, María, et al.
Publicado: (2019)

The Role of Methylation of Host and/or Human Papillomavirus (HPV) DNA in Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Lesions
por: Dovnik, Andraž, et al.
Publicado: (2023)

CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology
por: Pesic, Aleksandra, et al.
Publicado: (2019)

The clinical course of untreated CIN2 (HPV16/18+) under active monitoring: A protocol of systematic reviews and meta-analysis
por: Han, Buwei, et al.
Publicado: (2023)

Serum Se, Ni, and As are associated with HPV infection and CIN2+ among Uyghur women in rural China
por: Abulizi, Guzhalinuer, et al.
Publicado: (2018)

Predictive Role of Telomerase Activity in the Clinical Outcome of Patients with Benign Lesions of the Uterine Cervix or CIN
por: Bravaccini, Sara, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0ju5u1q84p5tq4p63vfo9j85hd